JP6936226B2 - フルオロカーボンナノエマルジョンの組成物 - Google Patents

フルオロカーボンナノエマルジョンの組成物 Download PDF

Info

Publication number
JP6936226B2
JP6936226B2 JP2018531107A JP2018531107A JP6936226B2 JP 6936226 B2 JP6936226 B2 JP 6936226B2 JP 2018531107 A JP2018531107 A JP 2018531107A JP 2018531107 A JP2018531107 A JP 2018531107A JP 6936226 B2 JP6936226 B2 JP 6936226B2
Authority
JP
Japan
Prior art keywords
nanoemulsion
certain embodiments
solution
compound
fluorocarbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502682A5 (enExample
JP2019502682A (ja
Inventor
エヴァン， シー． アンガー，
エヴァン， シー． アンガー，
エドムンド アール． マリネッリ，
エドムンド アール． マリネッリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvox Pharma LLC
Original Assignee
Nuvox Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvox Pharma LLC filed Critical Nuvox Pharma LLC
Publication of JP2019502682A publication Critical patent/JP2019502682A/ja
Publication of JP2019502682A5 publication Critical patent/JP2019502682A5/ja
Application granted granted Critical
Publication of JP6936226B2 publication Critical patent/JP6936226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L27/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers
    • C08L27/02—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment
    • C08L27/12—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment containing fluorine atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2018531107A 2015-12-21 2016-12-20 フルオロカーボンナノエマルジョンの組成物 Active JP6936226B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562270226P 2015-12-21 2015-12-21
US62/270,226 2015-12-21
PCT/US2016/067650 WO2017112614A1 (en) 2015-12-21 2016-12-20 Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof

Publications (3)

Publication Number Publication Date
JP2019502682A JP2019502682A (ja) 2019-01-31
JP2019502682A5 JP2019502682A5 (enExample) 2020-01-16
JP6936226B2 true JP6936226B2 (ja) 2021-09-15

Family

ID=59089857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531107A Active JP6936226B2 (ja) 2015-12-21 2016-12-20 フルオロカーボンナノエマルジョンの組成物

Country Status (11)

Country Link
US (3) US11304899B2 (enExample)
EP (1) EP3393459A4 (enExample)
JP (1) JP6936226B2 (enExample)
KR (2) KR20240100472A (enExample)
CN (2) CN108697664A (enExample)
AU (2) AU2016377361B2 (enExample)
BR (1) BR112018012618A2 (enExample)
CA (1) CA3009404C (enExample)
EA (1) EA201891296A1 (enExample)
IL (2) IL260206B2 (enExample)
WO (1) WO2017112614A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102342326B1 (ko) * 2020-12-11 2021-12-23 애경케미칼주식회사 계면장력이 우수한 불소계 계면활성제 조성물
KR102342324B1 (ko) 2020-12-11 2021-12-23 애경케미칼주식회사 불소계 계면활성제 조성물
AU2024260092A1 (en) * 2023-04-26 2025-10-23 Swaza Inc. Nanoparticle composition for oxygen delivery
CN116622338A (zh) * 2023-06-05 2023-08-22 西安科技大学 井下复合型降尘防爆一体化处理材料及其制备方法和应用
KR20250101952A (ko) * 2023-12-27 2025-07-04 (주)아이엠디팜 과불화탄소와 카제인을 함유한 산소운반체 약학조성물 및 그의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP6431671B2 (ja) * 2011-03-04 2018-11-28 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 発作および虚血療法としてのドデカフルオロペンタンエマルション
US10279053B2 (en) * 2011-07-19 2019-05-07 Nuvox Pharma Llc Microbubble compositions, method of making same, and method using same
WO2013043236A1 (en) * 2011-09-22 2013-03-28 Rockland Technimed, Ltd. Compositions and methods useful for realtime in situ physiological molecular imaging of oxygen metabolism
US8822549B2 (en) * 2011-10-13 2014-09-02 Jennifer L. Johnson Buffered oxygen therapeutic
JP6728050B2 (ja) * 2014-03-05 2020-07-22 アンガー， エヴァン， シー．ＵＮＧＥＲ， Ｅｖａｎ， Ｃ． 分割放射線療法および化学療法と併用する酸素療法剤、その使用方法、およびそれを含む薬剤
AU2015274259B2 (en) * 2014-06-12 2019-04-18 Evan C. Unger Phospholipid composition and microbubbles and emulsions formed using same
HUE043680T2 (hu) * 2014-12-18 2019-09-30 Bracco Suisse Sa Célbajuttató gázzal töltött mikrorészecske készítmény

Also Published As

Publication number Publication date
WO2017112614A1 (en) 2017-06-29
US20220401364A1 (en) 2022-12-22
BR112018012618A2 (pt) 2018-12-04
CN118662440A (zh) 2024-09-20
CA3009404C (en) 2023-12-12
IL260206A (en) 2018-07-31
EP3393459A4 (en) 2019-10-02
AU2016377361A1 (en) 2018-07-05
IL298236A (en) 2023-01-01
US20180360754A1 (en) 2018-12-20
AU2016377361B2 (en) 2022-07-07
KR102679118B1 (ko) 2024-06-26
AU2022235555B2 (en) 2024-11-14
KR20240100472A (ko) 2024-07-01
KR20180132605A (ko) 2018-12-12
IL298236B1 (en) 2024-01-01
IL260206B (en) 2022-12-01
US20250248937A1 (en) 2025-08-07
IL298236B2 (en) 2024-05-01
JP2019502682A (ja) 2019-01-31
AU2022235555A1 (en) 2022-10-13
CN108697664A (zh) 2018-10-23
EP3393459A1 (en) 2018-10-31
EA201891296A1 (ru) 2019-01-31
US11304899B2 (en) 2022-04-19
CA3009404A1 (en) 2017-06-29
IL260206B2 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
AU2022235555B2 (en) Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
US20230139672A1 (en) O/w-emulsions comprising semifluorinated alkanes
JP5668004B2 (ja) ２，６−ジイソプロピルフェノール（プロポフォール）の水性医薬組成物およびその使用
ES2606585T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
SK124797A3 (en) Oil in water emulsions containing propofol and edetate
JP2018515484A (ja) カバジタキセル脂肪乳剤注射剤、その調製方法およびその使用
CN102038635A (zh) 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
US9539219B2 (en) Pharmaceutical compositions of carotenoid chylomicrons
CN106109412A (zh) 氟比洛芬酯脂微球注射液及其制备方法
EA040209B1 (ru) Способ получения водной фторуглеродной наноэмульсии
WO2010082092A1 (en) Propofol based anesthetic with preservative
CN110548004A (zh) 一种稳定的丁苯酞大容量注射液及其制备方法
RU2329788C2 (ru) Перфторуглеродно-жировые эмульсии с газотранспортными и энергетическими свойствами для медицинского назначения: состав, способ получения и средство для лечения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210826

R150 Certificate of patent or registration of utility model

Ref document number: 6936226

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250